Flow Semaglutide: Is This the Same as Wegovy?

What does "flow semaglutide" actually mean?

The honest answer is that no UK-licensed product uses "flow" as part of its name for semaglutide. Wegovy is the brand the MHRA has authorised for weight management, made by Novo Nordisk. In some overseas markets, pharmaceutical distributors or compounding services have adopted informal names or brand descriptors that include words like "flow" to describe semaglutide formulations, none of those products hold a UK marketing authorisation.

If you encountered "flow semaglutide" through social media, a forum, or an international website, it is worth pausing. The MHRA has consistently warned that weight-loss medicines sold online through unverified channels often carry serious risks, including counterfeits. Reporting suspect sellers can be done directly via the MHRA Yellow Card scheme, which exists precisely for this kind of concern.

The semaglutide products you can legally obtain in the UK for weight loss are Wegovy (once-weekly injection) and, since June 2026, the Wegovy tablet. Both require a prescription following a clinical assessment. Our Wegovy overview covers both formulations in detail, including what the dose schedule looks like and what the trial evidence shows.

How does semaglutide work, and what does the evidence say?

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a gut hormone released after eating; it signals fullness to the brain, slows how quickly food leaves the stomach, and helps regulate blood sugar. Semaglutide mimics that signal, maintaining it at levels the body would not naturally sustain after a meal.

The pivotal evidence comes from the STEP programme. In the STEP 1 trial, 68 weeks of 2.4 mg weekly semaglutide alongside lifestyle changes produced an average weight reduction of around 15%, a result published in the New England Journal of Medicine and which underpins the NICE recommendation for Wegovy. A question our prescribers hear regularly is whether results differ much between individuals; the short answer is yes, they do, which is one reason why ongoing clinical oversight matters throughout treatment.

For a broader picture of how semaglutide sits alongside other licensed options, our semaglutide guide works through the mechanism, the licensed schedule and the side-effect profile in plain language. If you are specifically curious about the 2 mg dose and what it involves, our page on semaglutide 2 mg covers the details clearly. If you are specifically curious about how the eye-health question intersects with semaglutide, this page on semaglutide and eyes covers what the current evidence does and does not say.

Who is Wegovy (semaglutide) licensed for in the UK?

The licensed eligibility criteria for Wegovy sit at a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes, raised cholesterol or obstructive sleep apnoea. For some ethnic backgrounds, UK guidance applies thresholds around 2.5 kg/m² lower. BMI alone does not settle the question; a prescriber looks at the full clinical picture, including any contraindications or medicines that might interact.

Semaglutide is not recommended during pregnancy, when breastfeeding, or for anyone actively trying to conceive. It is not licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma or MEN2 should discuss this with a clinician before considering any GLP-1 medicine. The NHS England guidance on weight management injections sets out additional clinical considerations, including advice on contraception and HRT for people starting treatment.

If you are weighing up whether semaglutide or another option suits your situation, our treatment overview compares the licensed routes available through nume (sorry, through our service) clearly and without pressure. We know it can feel overwhelming when you have done a lot of searching and are still not sure what applies to you in the UK. That feeling is common, and it is exactly what a free clinical consultation is designed to sort out.

Does the price or source of semaglutide matter?

For a prescription medicine, the origin and oversight of supply matters more than the headline figure. Semaglutide sold through channels that bypass a prescriber is not a shortcut; it is an unknown. Counterfeit and unlicensed GLP-1 pens have been found to contain incorrect or dangerous substances, and the MHRA has carried out significant enforcement action in the UK as a result.

Legitimate private treatment through a GPhC-registered pharmacy includes prescription, dispensing from the licensed UK supply chain, and clinical review before every order. If you want to understand what a realistic private cost looks like and what it covers, our Wegovy cost page addresses the price question honestly, including what headline figures often leave out.

For anyone who wants to check exactly which dose schedule applies, the starting-dose page explains why semaglutide treatment opens at 0.25 mg and how the titration works over time. The clinical team behind our service is described on our clinical team page if you want to know more about who reviews consultations before anything is dispensed.